CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
David Cescon MD, PhD, is a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre, where his clinical practice is devoted to the care of patients with breast cancer. His research integrates laboratory and clinical studies, focused on the identification of breast cancer therapeutic vulnerabilities and determinants of drug response and resistance.
The first PALLAS Research Project Proposal Call is now open for submissions from Sep. 15th 2021 until Jan. 15th 2022. All PALLAS|MA37 investigators are eligible to submit a Research Project Proposal on available PALLAS data and samples, addressing questions that go beyond protocol defined objectives.
At the recent European Society For Medical Oncology (ESMO 21) Congress held September 16 -21, Dr. Thierry Conroy presented the updated results of the Unicancer PRODIGE 24/CCTG PA6 trial. The five-year data from the trial has confirmed the significant benefits of the use of mFOLFIRINOX chemotherapy in all outcomes.
This practice-changing research confirmed the significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy regimen compared to the then standard treatment with gemcitabine.
So much has happened recently that I wanted to take a moment to update everyone on key accomplishments and our group aims for future.
The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group" has been published in Current Oncology https://www.mdpi.com/1718-7729/28/5/311/pdf
Kelvin K. W. Chan, Matthew C. Cheung, Dean A. Regier, Annette Hay, Alexander V. Louie, Winson Y. Cheung, Jean-Eric Tarride , Suji Udayakumar and Nicole Mittmann
Please be aware of the permanent closure of the MDC.1 (S1117) trial: A Randomized Phase II/III Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Under the supervision of the Compliance Group Team Leader, the Cancer Research Monitor/Auditor will conduct quality control and assurance activities for clinical trials in North America, providing support to both the monitoring and audit programs of the Canadian Cancer Trials Group, as required.
